Equity Overview
Price & Market Data
Price: $3.35
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $4,429,906
Volume: 0
Performance Metrics
1 Week: 2.45%
1 Month: 20.07%
3 Months: -15.62%
6 Months: -39.42%
1 Year: -75.20%
YTD: -27.96%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Denmark
Details
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.